Playback speed
10 seconds
Long-Term Management on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010
By
Beacon Medical Interchange
FEATURING
Jack West
By
Beacon Medical Interchange
FEATURING
Jack West
607 views
November 16, 2018
Dr. Jack West reviews longitudinal outcomes for patients on the KEYNOTE-010 trial of pembrolizumab (Keytruda) ...
read more ↘ vs. docetaxel as 2nd line therapy for advanced NSCLC, with helpful new info on those completing 2 years of pembro & implications for practice.
↖ read less
read more ↘ vs. docetaxel as 2nd line therapy for advanced NSCLC, with helpful new info on those completing 2 years of pembro & implications for practice.
↖ read less
Comments 0
Login to view comments.
Click here to Login
Lung